Revenue segments as reported by the company.

Net revenue, before excise taxes

Excise taxes

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

Research and development

General and administrative

Restructuring costs

Share-based payments

Depreciation and amortization

Impairment loss on goodwill and indefinite-lived intangible assets

Impairment loss on long-lived assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cronos Group

Cronos Group, Inc. engages in the production and distribution of cannabis. Its brands include PEACE NATURALS, COVE, Spinach, Lord Jones, and PEACE+. The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cronos Group, Inc. engages in the production and distribution of cannabis. I It operates through the Canada and Israel segments. The company was founded on August 21, 2012 and is headquartered in Toronto, Canada.

Aurora Cannabis

Canopy Growth

Tilray Brands

Investors will have to wait until 2021 for any shot at profitability with this marijuana stock.

Which Pot Stock -- Aurora, Canopy, Tilray, or Cronos -- Will Be Profitable Last?

Cronos Group, Inc. (CRON) CEO Mike Gorenstein on Q4 2018 Results - Earnings Call Transcript

Here's what investors still don't know after Cronos Group reported its Q4 results.

4 Big Questions for Cronos Group After Its Q4 Earnings Update

Shares of Canadian pot company Cronos slid 5 percent Tuesday after the company reports disappointing fourth-quarter revenue.

Shares of Canadian pot company Cronos slide after revenue disappoints

Recreational marijuana sales and increased cannabis oil sales fueled revenue growth, but the company's costs are going up.

Cronos Group Reports Q4 Loss As Revenue Jumps

These stocks overcame a mixed market. Find out how.

Why Cronos Group Jumped Today

According to Wall Street, the choice is pretty simple.

Which Pot Stock -- Aurora, Canopy, Cronos, or Tilray -- Has the Most Upside?

HEXO Corp

CBD currently exists in a legal gray area, locking small entrepreneurs out of the market.

Government Crackdowns Puts Smaller CBD Vendors In Jeopardy

GW Pharmaceuticals

Legalization has long been considered a boon for the marijuana industry.

US Marijuana Industry to Flourish in 2019: Who Gains?

With the cigarette giant's investment in the cannabis company complete, it's up to Cronos to perform.

Will Cronos Group Earnings Get an Altria Bump?

Find out if further gains are around the corner.

These Marijuana Stocks Have Doubled So Far in 2019: Cronos

The analysts are down on Cronos. Should you be, too?

Is Cronos Group Stock Too Expensive to Buy?

The cannabis industry faces a rare opportunity as the drug heads toward a potential rescheduling in the United States. A new Roth Capital report suggests that multistate operators (MSOs) are the most promising companies in the space.

Roth Sees Rare Opportunity For Cannabis Industry, MSOs

Popular pot stocks don't always make for the best investments.

Buy OrganiGram Holdings, Not Cronos Group

Wall Street is beginning to weigh in on the marijuana industry, and investors may not like what they hear.

3 Pot Stocks Wall Street Thinks You Should Sell

Altria

Tobacco company Altria Group's C$2.4-billion ($1.8 billion) investment in cannabis mega player Cronos Group.

Different Smokes For Different Folks: The Industry Reaction To Altria's $1.8B Cronos Group Investment

The cannabis company is enjoying torrid gains following a blockbuster deal with a tobacco titan.

Why Marijuana Stock Cronos Group Has Skyrocketed 104% So Far in 2019

Aphria

Therapix Biosciences

Zynerba Pharmaceuticals

There is a lot of hype regarding CBD and a lack of regulatory clarity. I discuss the big issues and identify some of the better players in the space among public-traded companies.

Investing In CBD Stocks Offers Opportunity But Risks

Amyris

Cannabinoids that don't require cannabis just might make these stocks huge winners in the future.

A Massive Disruption Could Be on the Way for Marijuana: 3 Stocks Poised to Profit

News for Cronos Group Stock (CRON)